Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and RTK/RAS Pathway Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SHP2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SHP2 (PTPN11) WT / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View SHP2 Products |
| Gene Delivery | SHP2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View SHP2 Products |
| Benchmark Ab | Anti-SHP2 Control Antibody Recombinant positive control. |
View SHP2 Products |
| Validator | SHP2 siRNA Set For knockdown verification. |
View SHP2 Products |
| Related Target A | KRAS Downstream synergistic target in the MAPK pathway. |
View KRAS Products |
| Related Target B | EGFR Upstream RTK often driving resistance bypass. |
View EGFR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Testing Activating Mutations | Recombinant mutant proteins (e.g., E76K, D61Y) available with >95% purity |
| Enzymatic Activity Assays | Native conformation preserved for accurate phosphatase activity screening |
| Lack of Controls | Recombinant positive control antibodies included |
| False Positives | Validated siRNA included for specificity checks |
Live SHP2 (PTPN11) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SHP2 therapeutics is intensifying, with major players focusing heavily on allosteric small molecule inhibitors. As a critical node connecting multiple Receptor Tyrosine Kinases (RTKs) to the RAS/MAPK pathway, SHP2 is a prime target for overcoming resistance to KRAS and EGFR inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting combination therapies and novel protein degraders (PROTACs) to overcome acquired resistance mutations.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Novartis (TNO155), Revolution Medicines (RMC-4630), Jacobio (JAB-3312) | Solid Tumors, NSCLC | Selectivity Assay (Need Mutant vs WT Proteins) |
| PROTAC / Degrader | Early-stage Biotech & Academic | Refractory Solid Tumors | Degradation Validation (Need high-purity proteins & Abs) |
| Combination Therapy | BridgeBio (BBP-398), Pfizer (PF-07284892) | KRAS-mutant Cancers | Pathway Analysis (Need related target proteins) |